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Abstract
Photodynamic therapy (PDT) is a local photochemical tumor treatment that consists of a photosensitizing agent in
combination with laser irradiation of a distinct wavelength. In some case reports and small non-randomized pilot studies,
PDT has proved feasible in patients with hilar bile duct cancer. Those studies showed an astonishing long survival time of
the treated patients. In the yet published two randomized controlled studies, PDT showed a significant extension of survival
compared to sole bile duct stenting. A possible explanation for this improved survival is a suspected anti-tumor
immunological effect induced by PDT. PDT reaches the same level of survival time as incomplete resection. The main
complication is a high risk of severe bacterial cholangitis and liver abscesses requiring peri-interventional antibiotics. Skin
phototoxicity, which at the beginning of PDT was the most dreaded potential complication, seems to play an ancillary role
using mild light protection. As the available photosensitizers, mainly hematoporphyrin derivative (HPD), are not very
effective in terms of depth of tumor necrosis, newer photosensitizers with light absorption in the near infrared spectrum and
therefore deeper penetration depth are currently under investigation.
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Technical aspects of photodynamic therapy
Photodynamic therapy (PDT) is a local ablative
method of treating dysplasia or neoplasia. It is more
or less selective accumulation of a photoactive drug
(photosensitizer) in tumor tissue followed by light
activation of the retained photosensitizer using an
adequate wavelength. The resulting tumor necrosis is
based on disturbance of the microvasculature and
degradation of membranes and lysosomes mediated
by cytotoxic radicals, mainly singlet oxygen [1].
Hematoporphyrin derivatives (HPD; e.g. Photosan-
3†, Photofrin II†) have been the most commonly
used photosensitizers. The depth of the ablative effect
is limited by the absorption characteristics of the
photosensitizer used and by the resulting penetration
depth of the appropriate wavelength. The depth of
tumor necrosis after HPD-PDT is therefore limited to
46 mm. Light activation is performed in the time
frame between 48 and 96 h after systemic adminis-
tration of HPD (2 mg/kg b.w.) by a quartz fiber
mounted with a cylindrical diffuser tip of 27 cm
length coupled to a dye laser or, more recently, diode
laser emitting a wavelength of 630 nm. The energy
density applied varies between 180 and 240 J/cm2.
Light activation can be done by transpapillary access
performing an ERCP or by percutaneous access
performing PTCD. Photosensitizers are also retained
by the skin, thus leading to a certain light sensitivity
and potential phototoxicity as the only known specific
side effect of PDT. Using HPD, the phototoxicity lasts
for 46 weeks in decreasing intensity. 5-Aminolevu-
linic acid (5-ALA) is a precursor of the endogenous
photosensitizer Protoporphyrin IX, which is gener-
ated in the heme pathway. 5-ALA PDT exhibits
phototoxicity of only 2448 h with a limited tumor
necrosis depth of 2 mm [2].
Clinical studies
The first report on successful PDT in bile duct cancer
was a case report of a patient receiving 7 PDT
treatment sessions over a survival period of 4 years
[3]. Subsequent pilot studies using HPD as photo-
sensitizer showed feasibility of PDT in patients with
non-resectable bile duct cancer according to facilitate
endoscopic stenting and relieving jaundice and, what
is more, improvement of survival was suspected [46].
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In a small pilot study, 5-ALA failed to show any
significant effect on tumor necrosis and, therefore, in
contrast to esophageal neoplasia, was judged as
ineffective in bile duct cancer [2]. FDG-PET, which
was thought to be an effective tool for assessing the
anti-tumor effect of PDT in bile duct cancer, failed to
show efficiency [7]. In a retrospective study, patients
receiving PDT were compared with a historical group
of patients treated with self-expandable metal stents
and/or plastic prostheses. There was a trend of
improved survival in the PDT group which missed
statistical significance [8]. In a long-term follow-up
study, patients with distant metastases showed re-
duced survival compared to patients without distant
metastases, and most patients died due to tumor
progression after stable disease initially [9]. A non-
randomized study comparing percutaneous PDT
stenting with mere percutaneous stenting showed a
significantly longer survival of the PDT group [10].
There are two prospective randomized controlled
studies comparing PDT with biliary stenting. Ortner
et al. showed superior median survival in the PDT
group (493 versus 98 days; pB0.0001) and improve-
ment of Karnofski performance status [11]. This
study included mainly patients who showed unsuc-
cessful relief of bile duct obstruction with mere
stenting and was therefore criticized on the grounds
of potential bias [12]. Our own group confirmed the
positive effect on median survival of PDT (630 versus
210 days; p0.019) in the second prospective rando-
mized study [13], in which all non-resectable patients
were randomized, especially with successful biliary
drainage. Performance status did not improve, but
held over the entire period of observation in the PDT
group. The only specific complication of PDT is
phototoxicity of the skin. In the published clinical
studies, the rate of phototoxicity ranges between 0%
and 25% [2,46,811,1318]. Another reported com-
plication is an increased risk of bacterial cholangitis
and liver abscess. As this is also a potential complica-
tion of mere stenting, it is difficult to measure the
extent of PDT’s contribution to that complication. In
our randomized study, there is a significantly higher
proportion of cholangitis in the PDT group in
contrast to the results of Ortner et al. [11,13].
PDT has been tried as neoadjuvant therapy to
reduce preoperative local tumor extent, which showed
complete tumor necrosis within a layer of 46 mm,
but viable tumor cells in the deeper surroundings
[17]. Newer photosensitizers with an absorption in
the near infrared spectrum and therefore deeper
necrosis, e.g. meso-tetrahydroxyphenyl chlorine
(mTHPC) and bacteriochlorins, are currently under
investigation [1921]. In an uncontrolled study,
adjuvant PDT of residual tumor after surgical resec-
tion in 8 patients was promising [15].
Recently, the combination of PDT with stenting
showed comparable survival rates to R1 resection, but
with a considerably lower complication rate [18].
Consensus statements
. Palliative PDT in bile duct cancer improves
survival.
. PDT increases the risk of cholangitis and liver
abscess.
. Phototoxicity of the skin is of ancillary impor-
tance.
. PDT should be confined to patients without
distant metastases.
. PDT should be confined to patients with a tumor
extent of 53 cm in diameter.
References
[1] Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D,
Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst
1998;/90:/889905.
[2] Zoepf T, Jakobs R, Rosenbaum A, Apel D, Arnold JC,
Riemann JF. Photodynamic therapy with 5-aminolevulinic
acid is not effective in bile duct cancer. Gastrointest Endosc
2001;/54:/7636.
[3] McCaughan JS Jr, Mertens BF, Cho C, Barabash RD, Payton
HW. Photodynamic therapy to treat tumors of the extrahepatic
biliary ducts. A case report. Arch Surg 1991;/126:/1113.
[4] Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U,
Fusco V, et al. Photodynamic therapy of nonresectable
cholangiocarcinoma. Gastroenterology 1998;/114:/53642.
[5] Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR,
Schmidt F, et al. Photodynamic therapy for advanced bile duct
cancer: evidence for improved palliation and extended survi-
val. Hepatology 2000;/31:/2918.
[6] Zoepf T, Jakobs R, Arnold JC, Apel D, Rosenbaum A,
Riemann JF. Photodynamic therapy for palliation of nonre-
sectable bile duct cancer preliminary results with a new diode
laser system. Am J Gastroenterol 2001;/96:/20937.
[7] Muller D, Wiedmann M, Kluge R, Berr F, Mossner J, Sabri O,
et al. [Is 18F-FDG-PET suitable for therapy monitoring after
palliative photodynamic therapy of non-resectable hilar cho-
langiocarcinoma?]. Z Gastroenterol 2005;/43:/43943.
[8] Dumoulin FL, Gerhardt T, Fuchs S, Scheurlen C, Neubrand
M, Layer G, et al. Phase II study of photodynamic therapy and
metal stent as palliative treatment for nonresectable hilar
cholangiocarcinoma. Gastrointest Endosc 2003;/57:/8607.
[9] Wiedmann M, Berr F, Schiefke I, Witzigmann H, Kohlhaw K,
Mossner J, et al. Photodynamic therapy in patients with non-
resectable hilar cholangiocarcinoma: 5-year follow-up of a
prospective phase II study. Gastrointest Endosc 2004;/60:/68
75.
[10] Cheon YK, Cho YD, Baek SH, Cha SW, Moon JH, Kim YS,
et al. [Comparison of survival of advanced hilar cholangio-
carcinoma after biliary drainage alone versus photodynamic
therapy with external drainage]. Korean J Gastroenterol 2004;/
44:/2807.
[11] Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U,
Huster D, et al. Successful photodynamic therapy for non-
resectable cholangiocarcinoma: a randomized prospective
study. Gastroenterology 2003;/125:/135563.
[12] Gores GJ. A spotlight on cholangiocarcinoma. Gastroenterol-
ogy 2003;/125:/15368.
[13] Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation
of nonresectable bile duct cancer: improved survival after
photodynamic therapy. Am J Gastroenterol 2005;/100:/2426
30.
[14] Harewood GC, Baron TH, Rumalla A, Wang KK, Gores GJ,
Stadheim LM, et al. Pilot study to assess patient outcomes
following endoscopic application of photodynamic therapy for
162 T. Zoepf
advanced cholangiocarcinoma. J Gastroenterol Hepatol 2005;/
20:/41520.
[15] Nanashima A, Yamaguchi H, Shibasaki S, Ide N, Sawai T,
Tsuji T, et al. Adjuvant photodynamic therapy for bile duct
carcinoma after surgery: a preliminary study. J Gastroenterol
2004;/39:/1095101.
[16] Shim CS, Cheon YK, Cha SW, Bhandari S, Moon JH, Cho
YD, et al. Prospective study of the effectiveness of percuta-
neous transhepatic photodynamic therapy for advanced bile
duct cancer and the role of intraductal ultrasonography in
response assessment. Endoscopy 2005;/37:/42533.
[17] Wiedmann M, Caca K, Berr F, Schiefke I, Tannapfel A,
Wittekind C, et al. Neoadjuvant photodynamic therapy as a
new approach to treating hilar cholangiocarcinoma: a phase II
pilot study. Cancer 2003;/97:/278390.
[18] Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D,
Schoppmeyer K, et al. Surgical and palliative management
and outcome in 184 patients with hilar cholangiocarcinoma:
palliative photodynamic therapy plus stenting is comparable to
r1/r2 resection. Ann Surg 2006;/244:/2309.
[19] Pereira SP, Ayaru L, Rogowska A, Mosse A, Hatfield AR,
Bown SG. Photodynamic therapy of malignant biliary stric-
tures using meso-tetrahydroxyphenylchlorin. Eur J Gastroen-
terol Hepatol 2007;/19:/47985.
[20] Kiesslich T, Berlanda J, Plaetzer K, Krammer B, Berr F.
Comparative characterization of the efficiency and cellular
pharmacokinetics of Foscan- and Foslip-based photodynamic
treatment in human biliary tract cancer cell lines. Photochem
Photobiol Sci 2007;/6:/61927.
[21] Oertel M, Schastak SI, Tannapfel A, Hermann R, Sack U,
Mossner J, et al. Novel bacteriochlorine for high tissue-
penetration: photodynamic properties in human biliary
tract cancer cells in vitro and in a mouse tumour model.
J Photochem Photobiol B 2003;/71:/110.
Photodynamic therapy of cholangiocarcinoma 163
